河北
分享至
来源：格隆汇APP
诺和诺德的竞争对手渤健(BIIB.US)盘前拉升涨超6%。消息面上，诺和诺德公司称Evoke 3期试验未显示阿尔茨海默病进展的统计学显著减少。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
